The current study is also the first to reveal the metabolic and anti-tumor immunity roles of miR-22 in the liver; miR-22 targeted both hepatocytes and T cells by silencing HIF1α and increasing RA signaling, both of which have metabolic and anti-inflammatory effects. The gene discussed is HIF1A; the disease is neoplasm.